

MSN Labs launches affordable diabetes drug EMPAONE

18 October 2021 | News

A fully indigenous development



MSN Laboratories, based in Hyderabad, has launched empagliflozin tablets (SGLT2i), a promising drug in diabetic management, under the brand name 'EMPAONE'. The medicine will cost Rs 15.90 and Rs 18.90 for each 10 mg and 25 mg tablet respectively.

'EMPAONE' is intended to provide diabetes patients in need across India with an affordable and accessible therapeutic option. The launch of EMPAONE assumes a critical role particularly for patients suffering from Type 2 diabetes and who were also affected with COVID-19, as diabetes is a major comorbidity factor in such cases.

MSN has developed the Active Pharmaceutical Ingredient (API) & the finished dosage formulation (FDF) of EMPAONE at its in-house state-of-the-art R&D centre. The development is fully indigenous right from conceptualization to API development and FDF.